Free Trial
NASDAQ:ATXS

Astria Therapeutics Q2 2023 Earnings Report

Astria Therapeutics logo
$6.73 +0.05 (+0.75%)
As of 03:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Astria Therapeutics EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.50
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Astria Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Astria Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, August 7, 2023
Conference Call Time
4:00PM ET

Astria Therapeutics Earnings Headlines

New law could create $3.7 trillion tsunami.
During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.
See More Astria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Astria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astria Therapeutics and other key companies, straight to your email.

About Astria Therapeutics

Astria Therapeutics (NASDAQ:ATXS), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

View Astria Therapeutics Profile

More Earnings Resources from MarketBeat